potassium citrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4519	866-84-2

Description:

Molecule	Description
Synonyms: potassium citrate anhydrous potassium citrate tripotassium citrate	A powder that dissolves in water, which is administered orally, and is used as a diuretic, expectorant, systemic alkalizer, and electrolyte replenisher. Molecular weight: 306.39 Formula: C6H5K3O7 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 140.62 ALOGS: ROTB: None

Molecule

Description

Synonyms:

potassium citrate anhydrous
potassium citrate
tripotassium citrate

A powder that dissolves in water, which is administered orally, and is used as a diuretic, expectorant, systemic alkalizer, and electrolyte replenisher.

Molecular weight: 306.39
Formula: C6H5K3O7
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 140.62
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
4	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
April 30, 2021	EMA	Advicenne S.A.
Aug. 30, 1985	FDA	MISSION PHARMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
General physical health deterioration	110.89	19.54	96	3949	201306	63283671
Multiple fractures	71.08	19.54	25	4020	8593	63476384
Hypertonic bladder	60.86	19.54	18	4027	3570	63481407
Haematochezia	57.16	19.54	38	4007	53506	63431471
Therapeutic drug monitoring analysis not performed	47.34	19.54	12	4033	1340	63483637
Nephrolithiasis	42.88	19.54	29	4016	41955	63443022
Fall	38.44	19.54	80	3965	392254	63092723
Systemic infection	36.45	19.54	13	4032	4647	63480330
Product monitoring error	33.07	19.54	12	4033	4504	63480473
Anaemia	32.48	19.54	63	3982	293367	63191610
Dementia	26.70	19.54	16	4029	18778	63466199
Nasal polypectomy	25.15	19.54	4	4041	39	63484938
Dizziness	24.25	19.54	71	3974	429854	63055123
Gait disturbance	23.57	19.54	42	4003	183136	63301841
Product residue present	23.39	19.54	9	4036	3970	63481007
Balance disorder	22.00	19.54	27	4018	84395	63400582
Dehydration	21.35	19.54	39	4006	173315	63311662
Faeces soft	20.28	19.54	9	4036	5683	63479294
Anaemia of malignant disease	19.98	19.54	5	4040	530	63484447

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrolithiasis	64.16	21.78	38	3183	30295	34923415
General physical health deterioration	49.66	21.78	60	3161	128209	34825501
Tracheal pain	29.96	21.78	5	3216	45	34953665
Waist circumference increased	28.59	21.78	8	3213	898	34952812
Regurgitation	27.63	21.78	9	3212	1690	34952020
N-terminal prohormone brain natriuretic peptide increased	27.15	21.78	10	3211	2705	34951005
Vitamin B12 deficiency	26.66	21.78	11	3210	4020	34949690
Consciousness fluctuating	26.46	21.78	8	3213	1179	34952531
Respiratory tract haemorrhage	25.93	21.78	8	3213	1262	34952448
Aortic stenosis	25.83	21.78	11	3210	4347	34949363
Eye swelling	25.05	21.78	14	3207	9981	34943729
Oesophageal ulcer	25.02	21.78	10	3211	3371	34950339
Atrioventricular block	24.97	21.78	13	3208	8050	34945660
Dysuria	24.12	21.78	20	3201	27132	34926578
Oedema peripheral	23.98	21.78	41	3180	119771	34833939
Systemic infection	23.94	21.78	11	3210	5201	34948509
Interstitial granulomatous dermatitis	23.51	21.78	5	3216	177	34953533
Abdominal pain	22.83	21.78	48	3173	163570	34790140
Oropharyngeal discomfort	22.08	21.78	9	3212	3187	34950523
Pain	21.86	21.78	54	3167	204621	34749089

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
General physical health deterioration	164.09	17.37	153	6367	275085	79462783
Nephrolithiasis	78.99	17.37	51	6469	53240	79684628
Multiple fractures	66.71	17.37	25	6495	8001	79729867
Systemic infection	58.55	17.37	24	6496	9728	79728140
Hypertonic bladder	53.63	17.37	18	6502	4183	79733685
Therapeutic drug monitoring analysis not performed	53.45	17.37	15	6505	1921	79735947
Product monitoring error	43.73	17.37	19	6501	8887	79728981
Dehydration	37.16	17.37	70	6450	248117	79489751
Haematochezia	36.03	17.37	40	6480	87605	79650263
Oedema peripheral	35.12	17.37	69	6451	252219	79485649
Anaemia	34.78	17.37	97	6423	444918	79292950
Fall	33.98	17.37	102	6418	487527	79250341
Cardiac failure chronic	33.69	17.37	17	6503	11118	79726750
Dysuria	31.48	17.37	29	6491	50922	79686946
Tracheal pain	30.55	17.37	5	6515	45	79737823
N-terminal prohormone brain natriuretic peptide increased	26.17	17.37	11	6509	4744	79733124
Dizziness	25.91	17.37	98	6422	526343	79211525
Vitamin B12 deficiency	24.71	17.37	12	6508	7229	79730639
Waist circumference increased	24.62	17.37	8	6512	1681	79736187
Localised infection	24.41	17.37	22	6498	37553	79700315
Regurgitation	24.32	17.37	9	6511	2778	79735090
Respiratory tract haemorrhage	24.02	17.37	8	6512	1815	79736053
Interstitial granulomatous dermatitis	22.68	17.37	5	6515	237	79737631
Product residue present	22.24	17.37	9	6511	3527	79734341
Atrioventricular block	22.18	17.37	14	6506	14027	79723841
Nephrocalcinosis	21.43	17.37	7	6513	1495	79736373
Aortic stenosis	21.39	17.37	11	6509	7484	79730384
Consciousness fluctuating	19.57	17.37	7	6513	1962	79735906
Oesophageal ulcer	19.22	17.37	10	6510	6965	79730903
Dementia	19.17	17.37	16	6504	24643	79713225
Pain	19.03	17.37	110	6410	703692	79034176
Chronic kidney disease	18.71	17.37	25	6495	66129	79671739
Renal impairment	18.22	17.37	40	6480	157743	79580125
Pseudoporphyria	17.95	17.37	5	6515	623	79737245
Electrocardiogram abnormal	17.65	17.37	13	6507	16724	79721144

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A12BA02	ALIMENTARY TRACT AND METABOLISM MINERAL SUPPLEMENTS POTASSIUM Potassium
FDA MoA	N0000009986	Alkalinizing Activity
FDA EPC	N0000175896	Metabolic Alkalinizer
CHEBI has role	CHEBI:35498	diuretics
MeSH PA	D004232	Diuretics
MeSH PA	D005100	Expectorants
MeSH PA	D045283	Natriuretic Agents
MeSH PA	D019141	Respiratory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Renal tubular acidosis	indication	1776003	DOID:14219
Hypokalemia	indication	43339004
Uric acid renal calculus	indication	274401005
Calcium renal calculus	indication	427649000
Hypokalemia Prevention	indication
Calcium Oxalate Renal Calculi	indication
Calcium Phosphate Renal Calculi	indication
Cystinuria	off-label use	85020001	DOID:9266
Cystine Renal Calculi	off-label use
Metabolic alkalosis	contraindication	1388004
Anuria	contraindication	2472002	DOID:2983
Hypocalcemia	contraindication	5291005
Peptic ulcer	contraindication	13200003	DOID:750
Hyperkalemia	contraindication	14140009
Pulmonary edema	contraindication	19242006	DOID:11396
Myocardial infarction	contraindication	22298006	DOID:5844
Ventricular tachycardia	contraindication	25569003
Complete atrioventricular block	contraindication	27885002
Dehydration	contraindication	34095006
Hyperthyroidism	contraindication	34486009	DOID:7998
Acute hepatitis	contraindication	37871000
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypernatremia	contraindication	39355002
Gastrointestinal ulcer	contraindication	40845000
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Acidosis	contraindication	51387008
Congenital myotonia, autosomal dominant form	contraindication	57938005
Acute nephropathy	contraindication	58574008
Metabolic acidosis	contraindication	59455009
Diarrhea	contraindication	62315008
Arterial thrombosis	contraindication	65198009
Arteriosclerotic vascular disease	contraindication	72092001
Hyperchloremia	contraindication	74450001
Gastrointestinal hemorrhage	contraindication	74474003
Third degree burn injury	contraindication	80247002
Oliguria	contraindication	83128009
Kidney disease	contraindication	90708001	DOID:557
Gastrointestinal obstruction	contraindication	126765001
Partial atrioventricular block	contraindication	195039008
Acute pancreatitis	contraindication	197456007	DOID:2913
Impaired renal function disorder	contraindication	197663003
Myocardial dysfunction	contraindication	233928007
Gastroparesis	contraindication	235675006
Chronic diarrhea	contraindication	236071009
Hyporeninemic hypoaldosteronism	contraindication	236464008
Rhabdomyolysis	contraindication	240131006
Esophageal dysmotility	contraindication	266434009	DOID:9192
Benign prostatic hyperplasia	contraindication	266569009
Peripheral edema	contraindication	271809000
Familial hyperkalemic periodic paralysis	contraindication	304737009	DOID:14451
Primary adrenocortical insufficiency	contraindication	373662000
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Hypoxia	contraindication	389086002
Disorder of coronary artery	contraindication	414024009
Ketoacidosis in diabetes mellitus	contraindication	420422005	DOID:1837
Hypertensive urgency	contraindication	443482000
Azotemia	contraindication	445009001
Severe dehydration	contraindication	450316000
Genitourinary Tract Infections	contraindication
Esophageal Compression	contraindication

🐶 Veterinary Drug Use

Species	Use	Relation
Cattle	Dehydration associated with diarrhea	Indication
Cattle	Early treatment of scouring	Indication
Cattle	Treatment following intravenous fluid therapy	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Re-Sorb, Vytrate	Zoetis Inc.	6

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D05578	KEGG_DRUG
4017519	VANDF
CHEBI:64733	CHEBI
CHEMBL1200458	ChEMBL_ID
CHEMBL3989822	ChEMBL_ID
DB09125	DRUGBANK_ID
EE90ONI6FF	UNII
1374802	RXNORM
35532	MMSL
5328	MMSL
72288	MMSL
NOCODE	MMSL
d01423	MMSL
000746	NDDF
000766	NDDF
002330	NDDF
387450001	SNOMEDCT_US
78542000	SNOMEDCT_US
C0137996	UMLSCUI
D019357	MESH_DESCRIPTOR_UI
13344	PUBCHEM_CID
6100-05-6	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Potassium Citrate and Citric Acid	HUMAN PRESCRIPTION DRUG LABEL	2	0121-0676	SOLUTION	1100 mg	ORAL	unapproved drug other	12 sections
Potassium Citrate and Citric Acid	HUMAN PRESCRIPTION DRUG LABEL	2	0121-0676	SOLUTION	1100 mg	ORAL	unapproved drug other	12 sections
TRICITRATES	HUMAN PRESCRIPTION DRUG LABEL	3	0121-0677	SOLUTION	550 mg	ORAL	unapproved drug other	12 sections
TRICITRATES	HUMAN PRESCRIPTION DRUG LABEL	3	0121-0677	SOLUTION	550 mg	ORAL	unapproved drug other	12 sections
UROCIT-K	HUMAN PRESCRIPTION DRUG LABEL	1	0178-0600	TABLET, EXTENDED RELEASE	5 meq	ORAL	NDA	22 sections
UROCIT-K	HUMAN PRESCRIPTION DRUG LABEL	1	0178-0600	TABLET, EXTENDED RELEASE	5 meq	ORAL	NDA	22 sections
UROCIT-K	HUMAN PRESCRIPTION DRUG LABEL	1	0178-0600	TABLET, EXTENDED RELEASE	5 meq	ORAL	NDA	22 sections
UROCIT-K	HUMAN PRESCRIPTION DRUG LABEL	1	0178-0610	TABLET, EXTENDED RELEASE	10 meq	ORAL	NDA	22 sections
UROCIT-K	HUMAN PRESCRIPTION DRUG LABEL	1	0178-0610	TABLET, EXTENDED RELEASE	10 meq	ORAL	NDA	22 sections
UROCIT-K	HUMAN PRESCRIPTION DRUG LABEL	1	0178-0610	TABLET, EXTENDED RELEASE	10 meq	ORAL	NDA	22 sections
UROCIT-K	HUMAN PRESCRIPTION DRUG LABEL	1	0178-0615	TABLET, EXTENDED RELEASE	15 meq	ORAL	NDA	22 sections
UROCIT-K	HUMAN PRESCRIPTION DRUG LABEL	1	0178-0615	TABLET, EXTENDED RELEASE	15 meq	ORAL	NDA	22 sections
UROCIT-K	HUMAN PRESCRIPTION DRUG LABEL	1	0178-0615	TABLET, EXTENDED RELEASE	15 meq	ORAL	NDA	22 sections
Potassium Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0070	TABLET	5 meq	ORAL	NDA	22 sections
Potassium Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0070	TABLET	5 meq	ORAL	NDA	22 sections
Potassium Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0071	TABLET	10 meq	ORAL	NDA	22 sections
Potassium Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0245-0071	TABLET	10 meq	ORAL	NDA	22 sections
Potassium Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2682	TABLET, EXTENDED RELEASE	5 meq	ORAL	ANDA	21 sections
Potassium Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2682	TABLET, EXTENDED RELEASE	5 meq	ORAL	ANDA	21 sections
Potassium Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2729	TABLET, EXTENDED RELEASE	10 meq	ORAL	ANDA	21 sections
Potassium Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2729	TABLET, EXTENDED RELEASE	10 meq	ORAL	ANDA	21 sections
Potassium Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2742	TABLET, EXTENDED RELEASE	15 meq	ORAL	ANDA	21 sections
Potassium Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2742	TABLET, EXTENDED RELEASE	15 meq	ORAL	ANDA	21 sections
TRICITRATES	HUMAN PRESCRIPTION DRUG LABEL	3	17856-0677	SOLUTION	550 mg	ORAL	UNAPPROVED DRUG OTHER	12 sections
POTASSIUM CITRATE	HUMAN PRESCRIPTION DRUG LABEL	1	31722-129	TABLET, EXTENDED RELEASE	5 meq	ORAL	ANDA	16 sections
POTASSIUM CITRATE	HUMAN PRESCRIPTION DRUG LABEL	1	31722-130	TABLET, EXTENDED RELEASE	10 meq	ORAL	ANDA	16 sections
POTASSIUM CITRATE	HUMAN PRESCRIPTION DRUG LABEL	1	31722-132	TABLET, EXTENDED RELEASE	15 meq	ORAL	ANDA	16 sections
Potassium Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	42291-499	TABLET, EXTENDED RELEASE	10 meq	ORAL	ANDA	21 sections
Potassium Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	42291-500	TABLET, EXTENDED RELEASE	15 meq	ORAL	ANDA	21 sections
POTASSIUM CITRATEEXTENDED RELEASE	HUMAN PRESCRIPTION DRUG LABEL	1	42543-406	TABLET	5 meq	ORAL	ANDA	20 sections